Comparison of desogestrel/ethinyl estradiol plus spironolactone versus cyproterone acetate/ethinyl estradiol in the treatment of polycystic ovary syndrome: A randomized controlled trial

被引:11
|
作者
Leelaphiwat, Supatra [1 ]
Jongwutiwes, Theerayut [2 ]
Lertvikool, Srithean [2 ]
Tabcharoen, Chotika [2 ]
Sukprasert, Matchuporn [2 ]
Rattanasiri, Sasivimol [3 ]
Weerakiet, Sawaek [2 ]
机构
[1] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Pathol, Bangkok 10400, Thailand
[2] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Obstet & Gynecol, Bangkok 10400, Thailand
[3] Mahidol Univ, Ramathibodi Hosp, Fac Med, Res Ctr, Bangkok 10400, Thailand
关键词
combined oral contraceptive pills; cyproterone acetate; desogestrel; polycystic ovary syndrome; spironolactone; COMBINED ORAL-CONTRACEPTIVES; INSULIN-RESISTANCE; DERMATOLOGICAL MANIFESTATIONS; IDIOPATHIC HIRSUTISM; CLINICAL-EFFICACY; HORMONAL-THERAPY; DIANE; 35; FORMS; WOMEN; ACNE;
D O I
10.1111/jog.12543
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
AimTo compare the effects of ethinyl estradiol (EE) 30mcg/desogestrel 150mcg plus spironolactone 25mg/day (group A) versus EE 35mcg/cyproterone acetate 2mg (group B) on hyperandrogenism and metabolism in PCOS. MethodsThis was a randomized clinical study. Eighteen women in groups A and B received medications for three cycles. Acne score, androgens and metabolic parameters were assessed before and after treatment. ResultsOne and two women in groups A and B, respectively, were excluded from the study. Both groups had significantly decreased acne score and free androgen index, and increased sex hormone-binding globulin levels. Cholesterol and high-density lipoprotein were significantly increased in group B, and androstenedione was significantly decreased in group A. The regular withdrawal bleeding was obtained in both groups. ConclusionBoth regimens had quite similar efficacy on hyperandrogenism after three cycles of therapy and without any changes in metabolic parameters.
引用
收藏
页码:402 / 410
页数:9
相关论文
共 50 条
  • [1] Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome:: A randomized study
    Morin-Papunen, L
    Vauhkonen, I
    Koivunen, R
    Ruokonen, A
    Martikainen, H
    Tapanainen, JS
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (01): : 148 - 156
  • [2] The effect of ethinyl estradiol–cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome
    Ozgur Baris Gul
    Asli Somunkiran
    Oguz Yucel
    Fuat Demirci
    Ismail Ozdemir
    Archives of Gynecology and Obstetrics, 2008, 277 : 25 - 30
  • [3] Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism
    Sahin, Y
    Bayram, F
    Kelestimur, F
    Müderris, I
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1998, 21 (06) : 348 - 352
  • [4] Comparison of cyproterone acetate plus ethinyl estradiol and finasteride in the treatment of hirsutism
    Şahin Y.
    Bayram F.
    Keleştimur F.
    Müderris I.
    Journal of Endocrinological Investigation, 1998, 21 (6) : 348 - 352
  • [5] Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome
    Mitkov, M
    Pehlivanov, B
    Terzieva, D
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2005, 118 (02) : 209 - 213
  • [6] The effect of ethinyl estradiol-cyproterone acetate treatment on homocysteine levels in women with polycystic ovary syndrome
    Gul, Ozgur Baris
    Somunkiran, Asli
    Yucel, Oguz
    Demirci, Fuat
    Ozdemir, Ismail
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2008, 277 (01) : 25 - 30
  • [7] The Effects of Metformin, Ethinyl Estradiol/Cyproterone Acetate, and Metformin Ethinyl Estradiol/Cyproterone Acetate Combination Therapy on Carotid Artery Intima-media Thickness in Patients with Polycystic Ovary Syndrome
    Unal, Derya
    Demirci, Huseyin
    Yilmaz, Murat
    Kisa, Ucler
    Tulmac, Murat
    Guliter, Sefa
    ISTANBUL MEDICAL JOURNAL, 2020, 21 (01): : 47 - 52
  • [8] Comparison of ethinyl-estradiol plus cyproterone acetate Versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome
    Luque-Ramirez, Manuel
    Alvarez-Blasco, Francisco
    Botella-Carretero, José I.
    Martinez-Bermejo, Elena
    Lasuncion, Miguel A.
    Escobar-Morreale, Héctor F.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (07): : 2453 - 2461
  • [9] Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome:: A randomized study
    Morin-Papunen, LC
    Vauhkonen, I
    Koivunen, RM
    Ruokonen, A
    Martikainen, HK
    Tapanainen, JS
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (09): : 3161 - 3168
  • [10] Ethinyl estradiol-drospirenone vs ethinyl estradiol-drospirenone plus metformin in the treatment of lean women with polycystic ovary syndrome
    Cinar, Nese
    Harmanci, Ayla
    Bayraktar, Miyase
    Yildiz, Bulent O.
    CLINICAL ENDOCRINOLOGY, 2013, 78 (03) : 379 - 384